
Thyrocare Technologies Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Franchise business revenue grew about 20% YoY with 8% volume growth; remaining growth driven by price mix (Rahul Guha, Page 17).
- Price hikes were marginal at 4-5%, major growth achieved through mix of larger Aarogyam packages, Jaanch test menu, vitamins, etc.
- Jaanch brand (diagnostic packages) reached ₹1 crore per month within 3 months and targets ₹25-30 crores revenue next year (Page 13).
- Hospital channel expansion is slow with only 2-3 hospitals currently, business still learning and not material yet (Page 14).
- Nuclear business expected to reach profitability with ₹12-12.5 crores quarterly revenue by H1 FY 2025 (Page 10).
- Overall 10% consolidated revenue growth YoY (Page 5) with franchise business strong and partnership business growing excluding API and B2G.
- Operating leverage likely to start kicking in FY 2025 with EBITDA margin of 28-30% maintained currently (Page 9).
See what Thyrocare Technologies management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- Currently, Thyrocare has about ₹30 crores of debt with a three-year tenure against assets, with no bank guarantee or collateral.
- In the immediate next 3 to 6 months, there is no plan for further debt funding as the company has enough cash.
- Future CAPEX investments will be evaluated to decide between equity, cash, or debt, depending on the best available options.
- The management views taking debt for healthcare equipment financing as prudent and cost-effective compared to using equity.
- They are open to taking more term loans if needed for business CAPEX, but no firm decision has been made yet.
- No anticipated increase in dividends reflected in future plans.
See what Thyrocare Technologies management said on order book — free account, 30 seconds.
Capex plans
Yes- H1 FY24 CAPEX spent: Rs. 46 crores.
- - Rs. 16-17 crores on replacing 24 old machines.
- - Rs. 16 crores on lab infrastructure improvements and expansions.
- - Rs. 6 crores on LLP investments.
- - Remaining on IT and other CAPEX.
- H2 FY24 planned CAPEX:
- - Rs. 5 crores to replace older machines.
- - Rs. 5 crores on physical infrastructure and IT overhaul.
- - Rs. 10 crores on international expansion, primarily Tanzania lab setup.
- - Total anticipated Rs. 20 crores in H2 FY24.
- FY25 estimated CAPEX: Around Rs. 50 crores (mainly maintenance CAPEX and expansions).
- Capital advances of Rs. 16 crores given for other business plans.
- Philosophy: Prefer debt financing (currently Rs. 30 crores term loan) over equity for equipment funding to optimize capital allocation.
- Expansion focus includes Tanzania (JV incorporated) and potential future geographies in East Africa, Middle East.
Track Thyrocare Technologies — get its next earnings analysis in your feed
How does Thyrocare Technologies rank vs peers in Healthcare Services?
Pro featureHow does Thyrocare Technologies rank in Healthcare Services?
Compare Thyrocare Technologies against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Thyrocare Technologies's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.